San Diego, December 5, 2025
Capricor Therapeutics’ stock surged over 340% after positive results from its Phase 3 HOPE-3 trial for Deramiocel, a treatment for Duchenne muscular dystrophy (DMD). The trial demonstrated a 54% slower decline in upper limb function and a 91% improvement in heart function. Following these promising outcomes, financial analysts have raised their price targets significantly, revitalizing investor interest in the company. Capricor plans to resubmit its Biologics License Application to the FDA, aiming for approval for its innovative therapy.
San Diego, California
Capricor Therapeutics Sees Stock Surge after HOPE-3 Trial Success
Capricor Therapeutics’ stock has experienced a significant surge following the announcement of positive results from its Phase 3 HOPE-3 trial for Deramiocel, a treatment for Duchenne muscular dystrophy (DMD). The company’s shares rose by over 340% after the trial demonstrated substantial improvements in both skeletal and cardiac functions in patients.
The HOPE-3 trial, involving 106 participants, met its primary endpoint by showing a 54% slower decline in upper limb function compared to a placebo. Additionally, a key secondary endpoint revealed a 91% improvement in left ventricular ejection fraction, indicating enhanced heart function. These results address previous concerns raised by the FDA in a Complete Response Letter issued in July 2025, which had requested additional clinical data for approval. Capricor plans to resubmit its Biologics License Application (BLA) for Deramiocel, incorporating the new data from the HOPE-3 trial.
Market Reactions and Future Prospects
In response to the positive trial outcomes, financial analysts have raised their price targets for Capricor’s stock. Jones Trading increased its target from $29 to $51, while Alliance Global Partners upgraded the stock to a “Buy” rating with a price target of $48. These adjustments reflect growing confidence in Deramiocel’s potential as a first-in-class therapy for DMD cardiomyopathy, a leading cause of mortality in DMD patients.
Capricor’s recent success follows a challenging period earlier this year when the FDA declined to approve Deramiocel, leading to a significant drop in the company’s stock value. However, the positive results from the HOPE-3 trial have revitalized investor interest and bolstered the company’s prospects in the competitive biotech sector.
Importance of Innovative Therapies in Biotech
As Capricor moves forward with its regulatory submissions, the biotech industry and investors are closely monitoring the company’s progress, anticipating further developments in the treatment of Duchenne muscular dystrophy. Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, including Duchenne muscular dystrophy.
Current Stock Performance
As of December 5, 2025, Capricor Therapeutics Inc. (CAPR) is trading at $25.40, with an intraday high of $30.52 and a low of $23.06. The stock opened at $28.20, with a volume of 8,668,953 shares. The latest trade was recorded at 1:15 AM UTC.
Frequently Asked Questions (FAQ)
What are the results of Capricor’s Phase 3 HOPE-3 trial for Deramiocel?
The HOPE-3 trial demonstrated a 54% slower decline in upper limb function and a 91% improvement in left ventricular ejection fraction compared to a placebo, indicating significant benefits in both skeletal and cardiac functions for patients with Duchenne muscular dystrophy.
How has the stock market responded to Capricor’s recent trial results?
Capricor’s stock surged by over 340% following the announcement of positive results from the Phase 3 HOPE-3 trial, reflecting strong investor confidence in the company’s prospects.
What is Capricor’s plan regarding the FDA’s Complete Response Letter?
Capricor plans to resubmit its Biologics License Application for Deramiocel, incorporating the new data from the HOPE-3 trial, to address the concerns raised by the FDA in the Complete Response Letter issued in July 2025.
What is the significance of Deramiocel in treating Duchenne muscular dystrophy?
Deramiocel is a cell therapy that has shown potential as a first-in-class treatment for DMD cardiomyopathy, a leading cause of mortality in DMD patients, offering hope for improved outcomes in this underserved patient population.
How has Capricor’s stock been performing recently?
As of December 5, 2025, Capricor’s stock is trading at $25.40, with an intraday high of $30.52 and a low of $23.06, reflecting significant volatility following the recent trial results.
Key Features of Capricor’s Recent Developments
| Feature | Description |
|---|---|
| Phase 3 HOPE-3 Trial Results | Demonstrated a 54% slower decline in upper limb function and a 91% improvement in heart function compared to placebo in DMD patients. |
| FDA’s Complete Response Letter | Issued in July 2025, requesting additional clinical data for Deramiocel’s approval; Capricor plans to resubmit BLA with new trial data. |
| Stock Market Response | Stock surged over 340% following positive trial results, with analysts raising price targets to $48 and $51. |
| Company’s Focus | Developing cell and exosome-based therapeutics for rare diseases, including Duchenne muscular dystrophy. |
| Current Stock Performance | Trading at $25.40 as of December 5, 2025, with significant volatility following recent developments. |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
